RDY

Business Context and Reporting Period

Company: Dr. Reddy's Laboratories Limited (DRL)
Filing Type: Form 6-K (Quarterly Report)
Reporting Period: Quarter and Nine Months Ended December 31, 2025
Business Overview: DRL is a leading India-based pharmaceutical company with operations in Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others (including Aurigene Oncology). Principal markets include India, Russia, the United States, and Germany.

Key Financial Metrics

Currency: Indian Rupees (Rs.) in millions, unless otherwise noted. USD translations provided at Rs. 89.84 = $1.00.

Income Statement Highlights (Nine Months Ended Dec 31, 2025)

• Revenues: Rs. 260,771 million (USD $2,903 million), an 8% increase year-over-year.
• Gross Profit: Rs. 143,573 million (55.1% margin), compared to Rs. 143,165 million (59.5% margin) in the prior period.
• Operating Profit: Rs. 49,226 million (18.9% margin), down from Rs. 54,196 million (22.5% margin).
• Profit Before Tax: Rs. 52,826 million (20.3% margin).
• Net Profit: Rs. 40,261 million (15.4% margin), a 3% decrease from Rs. 41,373 million.
• EPS (Basic): Rs. 48.83 (USD $0.54).

Balance Sheet Highlights (As of Dec 31, 2025)

• Total Assets: Rs. 562,899 million (USD $6,266 million).
• Cash and Cash Equivalents: Rs. 18,657 million (USD $208 million).
• Total Liabilities: Rs. 187,143 million (USD $2,083 million).
• Short-term Borrowings: Rs. 50,286 million (USD $560 million).
• Long-term Borrowings: Rs. 11,608 million (USD $129 million).
• Total Equity: Rs. 375,756 million (USD $4,183 million).

Cash Flow Highlights (Nine Months Ended Dec 31, 2025)

• Operating Cash Flow: Net inflow of Rs. 41,110 million (USD $458 million).
• Investing Cash Flow: Net outflow of Rs. 39,027 million (USD $435 million), driven by purchases of investments and property, plant, and equipment.
• Financing Cash Flow: Net inflow of Rs. 1,251 million (USD $15 million).

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue grew 4% in the quarter and 8% for the nine months, driven by growth in Emerging Markets (Russia +36% for 9 months), Europe (+77% for 9 months, largely due to the Haleon NRT acquisition), and India (+14% for 9 months). This was partially offset by a 12% decline in North America revenues due to price erosion and volume decreases.
• Margin Compression: Gross profit margins declined from 59.5% to 55.1% (9 months) primarily due to price erosion in existing products, unfavorable product mix shifts, and lower government incentives.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 13% (9 months), attributed to higher personnel costs (including incremental costs from India's "New Labour Codes"), increased sales/marketing spend, and depreciation.
• Impairment Charges: Impairment of non-current assets was Rs. 933 million for the nine months, including a Rs. 535 million charge for property, plant, and equipment related to the discontinuation of conjugated estrogen development in New York.
• Acquisitions: The company completed the acquisition of Haleon's global Nicotine Replacement Therapy (NRT) business outside the U.S. in September 2024, contributing significantly to European revenue growth.

Guidance, Outlook, Risks, and Unusual Items

• Regulatory Inspections: The U.S. FDA conducted inspections at multiple facilities (Hyderabad, Miryalaguda, Middleburgh, Srikakulam, Mirfield). Most were classified as "Voluntary Action Indicated" (VAI). A Post Application Action Letter (PAAL) was received for the Biologics facility in Hyderabad in January 2026.
• Legal Contingencies:
  • Ranitidine Litigation: Over 3,275 lawsuits in MDL 2924. The company settled California cases (approx. 199 dismissed). Appeals in Illinois and federal courts are ongoing.
  • Antitrust Litigation: Named in MDL 2724 (Generic Drug Price Fixing) involving 23 drugs. Bellwether trials are anticipated in 2026.
  • Revlimid Litigation: Named in antitrust lawsuits regarding patent settlement agreements; motions to dismiss are pending.
  • Internal Investigation: Ongoing cooperation with the SEC and DOJ regarding an anonymous complaint from 2020 concerning potential FCPA violations in Ukraine and other markets.
• Geopolitical Risks: The company monitors the impact of conflicts in Russia and Ukraine. While revenue from Russia grew significantly, management expects to fully recover asset carrying amounts.
• Unusual Items:
  • Gain of Rs. 877 million recognized from the write-back of liabilities related to the discontinuation of the conjugated estrogen project.
  • Settlement of product-related litigations in the U.S. for Rs. 748 million.

Investor Verification Checklist

• North America Performance: Verify the extent of price erosion and volume decline in the U.S. generics market and its impact on future guidance.
• Regulatory Status: Monitor the outcome of the FDA Post Application Action Letter (PAAL) for the Hyderabad Biologics facility and the status of other VAI inspections.
• Legal Exposure: Assess the potential financial impact of the Ranitidine MDL 2924 appeals and the Generic Drug Price Fixing MDL 2724 bellwether trials scheduled for 2026.
• Acquisition Integration: Track the integration progress and revenue contribution of the Haleon NRT business, particularly the transfer of marketing authorizations expected by March 2026.
• India Labor Costs: Evaluate the long-term impact of the "New Labour Codes" on personnel costs and operating margins.